Licensing status

Publication and contact information

Drug platforms

Human neutralizing mAbs against Middle East respiratory syndrome coronavirus (MERS-CoV)

Human neutralizing mAbs against MERS-CoV could aid the development of new therapeutics to treat or prevent infection. A screen of a single-chain variable domain fragment (scFv) phage library yielded seven unique fragments that bind to the MERS-CoV spike protein. In a nonhuman primate cell line, the most potent human mAbs generated from the identified scFvs neutralized the MERS-CoV with IC50 values ranging from 1.25 to 2 mg/mL. Next steps could include optimizing the lead neutralizing mAb and evaluating it in models of MERS-CoV infection.

SciBX 7(21); doi:10.1038/scibx.2014.629
Published online May 29, 2014

Patent and licensing status unavailable

Tang, X.-C. et al. Proc. Natl. Acad. Sci. USA; published online
April 28, 2014;
Contact: Wayne A. Marasco, Dana-Farber Cancer Institute, Boston, Mass.